Characterization of HOL-30: a novel tandem-repeat galectin from the marine sponge Halichondria okadai
BBA Advances · 2025 · 7 · 100153
DOI: 10.1016/j.bbadva.2025.100153 ↗Kurz gefasst
Fachartikel in der Zeitschrift BBA Advances, 2025. Verfasst von Mayuka Ohkawa und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of NanoBiosciences, Yokohama City University, 22-2, Seto, Kanazawa-ku, Yokohama 236-0027, Japan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Government of Japan Ministry of Education Culture Sports Science and Technology, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
We here report the novel primary structure of a new member in the galectin family, the β-galactoside-binding lectin HOL-30, from the marine sponge Halichondria okadai, whose full-length sequence was determined thanks to the combination between Edman degradation and transcriptome analysis. The HOL-30 polypeptide is a tandem-repeat dimeric galectin, consisting of 281 amino acids, which includes two carbohydrate recognition domains (CRDs). Unlike most other galectins described in Porifera, HOL-30 did not have a signal peptide sequence for secretion. In solution, HOL-30 exhibited a molecular weight of 60 kDa, indicating a dimeric organization consisting of two 30 kDa tandem-repeat subunits stabilized by non-covalent interactions. Although the two CRDs had a similar predicted 3D structure, they displayed low pairwise sequence identity, approximately 20 %. HOL-30 exhibited glycan-binding affinities for type-1 (Galβ1-3GlcNAc) and type-2 (Galβ1-4GlcNAc) LacNAc. Furthermore, it also recognized blood type B-oligosaccharides on type-1 and type-2 LacNAc (Galα1-3Gal[Fucα1-2]β1-3/4GlcNAc), and blood type H-oligosaccharide on type-3 (Gal[Fucα1-2]β1-3GalNAcα). The glycan-binding properties of HOL-30 were compared with those of the hRTL galectin, previously identified in Chondrilla australiensis, consisting of tetrameric 15 kDa prototype subunits. The two sponge galectins displayed similar, but not identical, carbohydrate-binding properties, as evidenced by the fact that despite effectively binding to vertebrate cultured cells, HOL-30 had minimal impact on cell growth. Antiserum analysis revealed a mosaic distribution of HOL-30 in the parenchymal cells of sponge tissues within dense cell clusters surrounding the spicules.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate School of NanoBiosciences, Yokohama City University, 22-2, Seto, Kanazawa-ku, Yokohama 236-0027, Japan.
- Graduate School of Medical Life Science, Yokohama City University, 1-7-29, Suehiro, Tsurumi-Ku, Yokohama 230-0045 Japan.
- Department of Chemistry, Faculty of Science, University of Chittagong, Chittagong 4331 Bangladesh.
- Department of Life Sciences, University of Trieste, Via Licio Giorgieri 5 34127 Trieste, Italy.
- Graduate School of Pharmaceutical Sciences, Nagasaki International University, 2825-7, Huis Tem Bosch, Sasebo 859-3298 Nagasaki, Japan.
Förderung
- Government of Japan Ministry of Education Culture Sports Science and Technology
- Japan Society for the Promotion of Science
Zitieren
APA
Ohkawa, M., Kamata, K., Kawsar, S. M. A., Gerdol, M., Fujii, Y., & Ozeki, Y. (2025). Characterization of HOL-30: a novel tandem-repeat galectin from the marine sponge Halichondria okadai. BBA Advances, 7, 100153. https://doi.org/10.1016/j.bbadva.2025.100153
Vancouver
Ohkawa M, Kamata K, Kawsar SMA, Gerdol M, Fujii Y, Ozeki Y. Characterization of HOL-30: a novel tandem-repeat galectin from the marine sponge Halichondria okadai. BBA Advances. 2025;7:100153. doi:10.1016/j.bbadva.2025.100153
BibTeX
@article{Ohkawa2025,
author = {Ohkawa, Mayuka and Kamata, Kenichi and Kawsar, Sarkar M A and Gerdol, Marco and Fujii, Yuki and Ozeki, Yasuhiro},
title = {Characterization of HOL-30: a novel tandem-repeat galectin from the marine sponge Halichondria okadai},
journal = {BBA Advances},
year = {2025},
volume = {7},
pages = {100153},
doi = {10.1016/j.bbadva.2025.100153}
}
EUVIMED